Paolo Tarantino: Antibody drug conjugates (ADCs) are leading to relevant survival improvements for multiple types of cancer.

Paolo Tarantino, MD and researcher at the European Institute of Oncology and clinical research fellow at the Dana-Farber Cancer Institute, shared the following insights on Twitter:

“Antibody drug conjugates (ADCs) are leading to relevant survival improvements for multiple types of cancer. Yet, they have only partly fulfilled the promise of the “magic bullet”, given that they’re commonly burdened with chemotherapy-related side effects (e.g. nausea, neutropenia, alopecia) as well as some less understood toxicities.

Thanks to Medscape for this interview on ADCs toxicities and for highlighting our recent article published on Nature Reviews (for details click here).

Looking forward to discussing more about this important topic with Patricia LoRusso, Elisabeth De Vries, Raffaele Colombo, Anthony Tolcher at the upcoming AACR-NCI-EORTC “Triple Meeting” (Plenary Session II). (For details click here).

For details click here.
Source: Paolo Tarantino/LinkedIn